Primary brain lymphomas after kidney transplantation: Presentation and outcome

Transplantation

Volumn 76, Issue 6, 2003, Pages 930-937

  Snanoudj, Renaud ^a   Durrbach, Antoine ^a   Leblond, Véronique ^b   Caillard, Sophie ^c   De Ligny, Bruno Hurault ^d   Noel, Christian ^e   Rondeau, Eric ^f   Moulin, Bruno ^c   Mamzer Bruneel, Marie France ^g   Lacroix, Catherine ^a   Charpentier, Bernard ^a  

^a BICÊTRE HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL CIVIL   (France)

^d CHU Clemenceau   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f HÔPITAL TENON   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; COMPLEMENT COMPONENT C3D RECEPTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BRAIN LYMPHOMA; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; EPSTEIN BARR VIRUS; FEMALE; GRAFT SURVIVAL; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS DETECTION;

ADULT; ANTILYMPHOCYTE SERUM; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACRANIAL HYPERTENSION; KIDNEY TRANSPLANTATION; LYMPHOMA; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0141544966     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000079253.06061.52     Document Type: Article

References (32)

1. Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993; 12(6 pt 2): S328.
2. Penn I, First MR. Development and incidence of cancer following cyclosporine therapy. Transplant Proc 1986; 18 (2 suppl 1): 210.
3. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993 342: 1514.
4. Opelz G. Are post-transplant lymphomas inevitable? Nephrol Dial Transplant 1996; 11(10): 1952.
5. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85(2): 552.
6. Wilkinson AH, Smith JL, Hunsicker LG, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989; 47(2): 293.
7. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323(25): 1723.
8. Jamil B, Nicholls K, Becker GJ, et al. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 1999; 68(10): 1597.
9. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14(2): 214.
10. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59(2): 240.
11. Corn BW, Marcus SM, Topham A, et al. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 1997; 79(12): 2409.
12. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993; 119(11): 1093.
13. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98(8): 2339.
14. Camilleri-Broet S, Martin A, Moreau A, et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol 1998; 110(5): 607.
15. Brousset P, Chittal S, Schlaifer D, et al. Detection of Epstein-Barr virus messenger RNA in Reed-Sternberg cells of Hodgkin's disease by in situ hybridization with biotinylated probes on specially processed modified acetone methyl benzoate xylene (ModAMeX) sections. Blood 1991; 77(8): 1781.
16. Stephan JL, Le Deist F, Blanche S, et al. Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody. Transplantation 1992; 54(2): 246.
17. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8(7): 1277.
18. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16(3): 864.
19. Renoult E, Georges E, Biava MF, et al. Toxoplasmosis in kidney transplant recipients: report of six cases and review. Clin Infect Dis 1997; 24(4): 625.
20. Dina TS. Primary central nervous system lymphoma versus toxoplasmosis in AIDS. Radiology 1991; 179(3): 823.
21. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17(12): 3835.
22. Camilleri-Broet S, Davi F, Feuillard J, et al. AIDS-related primary brain lymphomas: histopathologic and immunohistochemical study of 51 cases. The French Study Group for HIV-Associated Tumors. Hum Pathol 1997; 28(3): 367.
23. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13(4): 961.
24. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19(3): 772.
25. Blay JY, Ongolo-Zogo P, Sebban C, et al. Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French Federation Nationale des Centres de Lutte contre le Cancer. Ann Oncol 2000; 11(suppl 1): 39.
26. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10(6): 877.
27. Chadburn A, Chen JM, Hsu DT, et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998; 82(10): 1978.
28. Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324(21): 1451.
29. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B- lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92(9): 3137.
30. DeAngelis LM, Yahalom J, Thaler HT, et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992; 10(4): 635.
31. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989; 39(6): 789.
32. Freilich RJ, Delattre JY, Monjour A, et al. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996; 46(2): 435.